13.22
-0.91
(-6.44%)
At close: January 10 at 4:00:01 PM EST
13.80
+0.58
+(4.39%)
After hours: 7:33:26 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 3 | 7 | 7 |
| Avg. Estimate | -0.09 | -0.38 | -1.44 | -1.74 |
| Low Estimate | -0.69 | -0.59 | -1.99 | -2.22 |
| High Estimate | 0.95 | -0.23 | -0.35 | -1.03 |
| Year Ago EPS | -0.2 | -0.42 | -1.72 | -1.44 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 2 | 8 | 8 |
| Avg. Estimate | 45.2M | 18.5M | 89.47M | 84.34M |
| Low Estimate | 12.32M | 10M | 57.6M | 46.4M |
| High Estimate | 120M | 27M | 165M | 121.72M |
| Year Ago Sales | 16.93M | 10.03M | 76.01M | 89.47M |
| Sales Growth (year/est) | 167.02% | 84.45% | 17.71% | -5.73% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.44 | -0.29 | -0.31 | -0.41 |
| EPS Actual | -0.2 | -0.42 | -0.49 | -0.39 |
| Difference | 0.24 | -0.13 | -0.18 | 0.02 |
| Surprise % | 54.77% | -43.84% | -58.92% | 4.53% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.09 | -0.38 | -1.44 | -1.74 |
| 7 Days Ago | -0.09 | 0 | -1.41 | -1.71 |
| 30 Days Ago | 0.17 | -0.5 | -1.05 | -1.47 |
| 60 Days Ago | 0.13 | -0.47 | -1.12 | -1.49 |
| 90 Days Ago | 0.13 | -0.45 | -1.12 | -1.47 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 1 | 1 |
| Up Last 30 Days | 3 | -- | 2 | 2 |
| Down Last 7 Days | 1 | 1 | 1 | -- |
| Down Last 30 Days | 1 | 1 | 2 | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ZYME | 53.90% | 8.73% | 16.12% | -20.78% |
| S&P 500 | 8.70% | 11.55% | 14.03% | 13.42% |
Upgrades & Downgrades
| Maintains | Wells Fargo: Equal-Weight to Equal-Weight | 12/19/2024 |
| Upgrade | JP Morgan: Neutral to Overweight | 12/16/2024 |
| Reiterates | HC Wainwright & Co.: Neutral to Neutral | 11/22/2024 |
| Upgrade | Leerink Partners: Market Perform to Outperform | 11/7/2024 |
| Maintains | Citigroup: Buy to Buy | 11/4/2024 |
| Reiterates | HC Wainwright & Co.: Neutral to Neutral | 11/1/2024 |
Related Tickers
ANAB AnaptysBio, Inc.
14.21
-1.04%
STOK Stoke Therapeutics, Inc.
9.00
+0.45%
QURE uniQure N.V.
13.85
-13.00%
ARVN Arvinas, Inc.
18.62
-6.05%
FDMT 4D Molecular Therapeutics, Inc.
5.52
-5.48%
DNLI Denali Therapeutics Inc.
19.10
-10.12%
JANX Janux Therapeutics, Inc.
46.76
-7.99%
ALXO ALX Oncology Holdings Inc.
1.7700
-4.32%
RVMD Revolution Medicines, Inc.
41.78
-5.94%
AGIO Agios Pharmaceuticals, Inc.
34.42
-4.12%